

# JPMorgan Funds - Global Healthcare Fund

Class: JPM Global Healthcare D (acc) - USD

**Synthetic risk and reward indicator** Based on share class volatility for the past 5 years. See Key Investor Information Document (KIID) for details.

1	2	3	4	5	6	7
Lower risk/ potential reward Not risk-free					Higher risk/ potential reward	

## Fund overview

ISIN LU0432979960 Bloomberg JPHLUD LX Reuters LU0432979960.LUF

**Investment objective:** To achieve a return by investing primarily in pharmaceutical, biotechnology, healthcare services, medical technology and life sciences companies ("Healthcare Companies"), globally.

### Investment approach

- Uses a research-driven investment process that is based on the fundamental analysis of companies and their future earnings and cash flows by a team of specialist sector analysts.
- Targets attractively valued companies using strong scientific rationale as the basis for all investment decisions.

Portfolio manager(s)	Fund assets	Domicile
Anne Marden	USD 2369.7m	Luxembourg
Matthew Cohen	NAV	Entry/exit charges
Laurence McGrath	USD 309.44	Entry charge (max) 5.00%
<b>Investment specialist(s)</b>	<b>Fund launch</b>	<b>Exit charge (max) 0.50%</b>
Frances Gerhold	2 Oct 2009	<b>Ongoing charge 2.71%</b>
<b>Fund reference</b>	<b>Class launch</b>	
currency USD	2 Oct 2009	
<b>Share class</b>		
currency USD		

## Fund ratings As at 29 February 2020


Morningstar Category™ Sector Equity Healthcare

## Performance


**1 Class:** JPM Global Healthcare D (acc) - USD

**2 Benchmark:** MSCI World Healthcare Index (Total Return Net)

**GROWTH OF USD 100,000 (in thousands) Calendar years**



### CALENDAR YEAR PERFORMANCE (%)



	2015	2016	2017	2018	2019	YTD
1	1.12	-16.25	18.91	1.50	20.18	-7.62
2	6.60	-6.81	19.80	2.51	23.24	-8.16

### RETURN (%)

	CUMULATIVE			ANNUALISED		
	1 month	3 months	1 year	3 years	5 years	10 years
1	-7.98	-4.85	1.03	7.48	1.51	12.17
2	-6.84	-5.03	5.56	8.74	5.25	11.41

### PERFORMANCE DISCLOSURES

*Past performance is not a guide to current and future performance. The value of your investments and any income from them may fall as well as rise and you may not get back the full amount you invested.*

Source: J.P. Morgan Asset Management. Share class performance is shown based on the NAV (net asset value) of the share class with income (gross) reinvested including actual ongoing charges excluding any entry and exit fees. The return of your investment may change as a result of currency fluctuations if your investment is made in a currency other than that used in the past performance calculation.

Indices do not include fees or operating expenses and you cannot invest in them.

The benchmark is for comparative purposes only unless specifically referenced in the Sub-Funds' Investment Objective and Policy.

See the material risks, general disclosures and definitions on pages 2 & 3.

### PORTFOLIO ANALYSIS

Measurement	3 years	5 years
Correlation	0.94	0.94
Alpha (%)	-1.16	-3.55
Beta	1.04	1.08
Annualised volatility (%)	13.55	14.81
Sharpe ratio	0.50	0.11
Tracking error (%)	4.62	5.13
Information ratio	-0.22	-0.65


## Holdings

### TOP 10

As at 31 January 2020

	Sector	% of assets
Johnson & Johnson	Pharmaceutical	7.6
UnitedHealth	Healthcare Services	5.9
Roche	Pharmaceutical	5.8
Bristol-Myers Squibb	Pharmaceutical	3.9
Novartis	Pharmaceutical	3.9
Novo Nordisk	Pharmaceutical	3.4
Eli Lilly	Pharmaceutical	3.2
AstraZeneca	Pharmaceutical	3.2
Thermo Fisher Scientific	Medtech	3.0
CIGNA	Healthcare Services	2.9

### MARKET CAP (%) (USD) As at 31 January 2020



### REGIONS (%)

		Compared to benchmark
North America	75.0	+6.7
Europe & Middle East ex UK	17.6	-0.9
United Kingdom	2.9	-1.5
Japan	1.1	-5.2
Emerging Markets	0.5	+0.5
Pacific ex-Japan	0.0	-2.5
Cash	2.9	+2.9

### SECTORS (%)

		Compared to benchmark
Pharmaceutical	37.1	-6.6
Biotechnology	21.5	+7.1
Medtech	21.4	-5.4
Healthcare Services	17.1	+2.0
Cash	2.9	+2.9

## Key risks

The Sub-Fund is subject to **Investment risks** and **Other associated risks** from the techniques and securities it uses to seek to achieve its objective. The table on the right explains how these risks relate to each other and the **Outcomes to the Shareholder** that could affect an investment in the Sub-Fund.

Investors should also read [Risk Descriptions](#) in the Prospectus for a full description of each risk.

### Investment risks Risks from the Sub-Fund's techniques and securities

Techniques	Securities
Concentration	Equities
Hedging	Smaller companies

### Other associated risks Further risks the Sub-Fund is exposed to from its use of the techniques and securities above

Currency	Liquidity	Market
----------	-----------	--------

### Outcomes to the Shareholder Potential impact of the risks above

Loss	Volatility	Failure to meet the Sub-Fund's objective.
Shareholders could lose some or all of their money.	Shares of the Sub-Fund will fluctuate in value.	

## GENERAL DISCLOSURES

**Before investing, obtain and review the current prospectus, Key Investor Information Document (KIID) and any applicable local offering document. These documents, as well as the annual and semi-annual reports and the articles of incorporation, are available free from your financial adviser, your J.P. Morgan Asset Management regional contact, the fund's issuer (see below) or at [www.jpmmam.lu](http://www.jpmmam.lu).**

This material should not be considered as advice or an investment recommendation. Fund holdings and performance are likely to have changed since the report date. No provider of information presented here, including index and ratings information, is liable for damages or losses of any type arising from use of their information. No warranty of accuracy is given and no liability in respect of any error or omission is accepted.

To the extent permitted by applicable law, we may record telephone calls and monitor electronic communications to comply with our legal and regulatory obligations and internal policies. Personal data will be collected, stored and processed by J.P. Morgan Asset Management in accordance with our EMEA Privacy Policy [www.jpmorgan.com/emea-privacy-policy](http://www.jpmorgan.com/emea-privacy-policy). For additional information on the sub-fund's target market please refer to the Prospectus.

## INFORMATION SOURCES

Fund information, including performance calculations and other data, is provided by J.P. Morgan Asset Management (the marketing name for the asset management businesses of JPMorgan Chase & Co. and its affiliates worldwide).

**All data is as at the document date unless indicated otherwise.**

© 2020 Morningstar. All Rights Reserved. The information contained herein:

(1) is proprietary to Morningstar; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

The historic performance shown relates to the Share Class 'JPM Global Healthtech D (acc) - USD' which was launched on 20/03/02 prior to the merger. This Sub-Fund JPMorgan Funds - Global Healthcare Fund has been launched with the assets of the JPMorgan Investment Funds - Global Healthtech Fund which has been merged into the Sub-Fund on 02/10/09. The historical performance shown corresponds to the historical performance of the former Sub-Fund JPMorgan Investment Funds - Global Healthtech Fund.

Benchmark Source: MSCI. Neither MSCI nor any other party involved in or related to compiling, computing or creating the MSCI data makes any express or implied warranties or representations with respect to such data (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of such data. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved, in or related to compiling, computing, or creating the data have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. No further distribution or dissemination of the MSCI data is permitted without MSCI's express written consent.

## ISSUER

JPMorgan Asset Management (Europe) S.à r.l., 6, route de Trèves, L-2633 Senningerberg, Luxembourg. B27900, corporate capital EUR 10.000.000.

---

**DEFINITIONS**

**Correlation** measures the relationship between the movement of the fund and its benchmark. A correlation of 1.00 indicates that the fund perfectly matched its benchmark.

**Alpha (%)** a measure of excess return generated by a manager compared to the benchmark. An alpha of 1.00 indicates that a fund has outperformed its benchmark by 1%.

**Beta** a measure of a fund's sensitivity to market movements (as represented by the fund's benchmark). A beta of 1.10 suggests the fund could perform 10% better than the benchmark in up markets and 10% worse in down markets, assuming all other factors remain constant.

**Annualised volatility (%)** an absolute measure of volatility and measures the

extent to which returns vary up and down over a given period. High volatility means that the returns have been more variable over time. The measure is expressed as an annualised value.

**Sharpe ratio** measures the performance of an investment adjusting for the amount of risk taken (compared a risk-free investment). The higher the Sharpe ratio the better the returns compared to the risk taken.

**Tracking error (%)** measures how much a fund's returns deviate from those of the benchmark. The lower the number the closer the fund's historic performance has followed its benchmark.

**Information ratio (IR)** measures if a manager is outperforming or underperforming the benchmark and accounts for the risk taken to achieve the returns. A manager who outperforms a benchmark by 2% p.a. will have a higher IR than a manager with the same outperformance but who takes more risk.